---
url: https://www.servicesaustralia.gov.au/leukaemia-chronic-myelomonocytic-leukaemia
title: Leukaemia - chronic myelomonocytic leukaemia - Health professionals - Services AustraliaServices AustraliaServices Australia
scrapedAt: 2026-02-20T21:41:08.220Z
source: servicesaustralia.gov.au
---
# Leukaemia - chronic myelomonocytic leukaemia

The PBS subsidises azacitidine and decitabine+cedazuridine for patients with chronic myelomonocytic leukaemia (CMML).

## on this page

-   [Patient eligibility](#a1)
-   [Section 100 arrangements](#a2)
-   [Authority applications](#a3)
-   [More information](#a4)

Please note: You’ll get an immediate assessment when you request [PBS authorities online](/apply-for-pbs-authority?context=20#accordion1).

## Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with azacitidine under the _National Health Act 1953_, section 100 and subsidises treatment with decitabine+cedazuridine under the _National Health Act 1953_, section 85 for patients with CMML.

Patients must be eligible for the [PBS](/pharmaceutical-benefits-scheme) and meet the relevant restriction criteria.

The [Schedule of Pharmaceutical Benefits](http://www.pbs.gov.au/pbs/home;jsessionid=jrrab7f28xtjycras12yiccu) on the PBS website outlines the restrictions for prescribing azacitidine and decitabine+cedazuridine.

## Section 100 arrangements

### Azacitidine

This item is only PBS-subsidised for non-admitted patients, day admitted patients or patients on discharge who are attending:

-   an approved private hospital
-   a public participating hospital
-   a public hospital.

This item isn’t PBS-subsidised for public hospital in-patients. You must include the hospital name and provider number on the authority application form.

## Authority applications

### Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised azacitidine to treat CMML can be made either in:

-   real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   writing and use [HPOS Form upload](/upload-forms-hpos?context=20)
-   writing and mail to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include the completed:

-   authority prescription form or forms
-   [chronic myelomonocytic leukaemia - azacitidine - initial authority application form](/pb079?context=20)
-   relevant attachments.

Applications for initial authority approval to prescribe PBS-subsidised decitabine+cedazuridine to treat CMML can be made either in:

-   real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   writing and use [HPOS Form upload](/upload-forms-hpos?context=20)
-   writing and mail to [PBS authority approvals](/health-professionals-contact-information?context=20#pbsauthority).

All written applications must include the completed:

-   authority prescription form or forms
-   [chronic myelomonocytic leukaemia - azacitidine - initial authority application form](/pb079?context=20)
-   relevant attachments.

### Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised azacitidine to treat CMML can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drug Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

Applications for continuing authority approval to prescribe PBS-subsidised decitabine+cedazuridine to treat CMML can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS authority approvals](/health-professionals-contact-information?context=20#pbsauthority) enquiry line.

## More information

Call the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs) for more information on azacitidine.

Call the [PBS Authority Approvals enquiry line](/health-professionals-contact-information?context=20#complexdrugs) for more information on decitabine+cedazuridine.
